A5029171340- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Renal Diseases and Glomerulopathies
- Transplantation: Methods and Outcomes
- Renal and Vascular Pathologies
- Organ Donation and Transplantation
- Neurological Complications and Syndromes
- Pregnancy and Medication Impact
- Cytomegalovirus and herpesvirus research
- Metabolism and Genetic Disorders
- Chronic Kidney Disease and Diabetes
- Pharmacological Effects and Toxicity Studies
- Polyomavirus and related diseases
- Complement system in diseases
- COVID-19 Clinical Research Studies
- Liver Disease and Transplantation
- Blood Pressure and Hypertension Studies
- Dialysis and Renal Disease Management
- Diabetes Treatment and Management
- Renal cell carcinoma treatment
- Renin-Angiotensin System Studies
- Blood groups and transfusion
- Pneumocystis jirovecii pneumonia detection and treatment
- SARS-CoV-2 and COVID-19 Research
- Organ and Tissue Transplantation Research
Vall d'Hebron Hospital Universitari
2015-2024
Universitat Autònoma de Barcelona
2015-2024
Spanish Clinical Research Network
2019-2023
Instituto de Salud Carlos III
2014-2023
Vall d'Hebron Institut de Recerca
2018-2023
Hebron University
2011-2019
Universidad de Navarra
2017
Astellas Pharma (United Kingdom)
2017
Astellas Pharma (United States)
2017
Catalan Society of Family and Community Medicine
2017
The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15-21 July 2005. Major outcomes included the elimination of non-specific term "chronic allograft nephropathy" (CAN) from classification for kidney pathology, and recognition entity chronic antibody-mediated rejection. Participation B cells rejection genomics markers were also major subjects addressed by conference.
Antibody-mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent treat AbAR, enabling excellent outcomes even patients highly sensitized donor prior transplant. It has become critical develop standardized criteria for pathological diagnosis of AbAR. This article presents international consensus classification AbAR based on discussions held at Sixth Banff Conference Allograft Pathology 2001....
The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications inflammation in areas interstitial fibrosis and tubular atrophy (i-IFTA) its relationship to T cell-mediated rejection (TCMR), continued evolution molecular diagnostics, particularly diagnosis antibody-mediated (ABMR). In confirmation previous studies, it was independently demonstrated by groups that i-IFTA is associated with reduced graft survival. Furthermore, these presented i-IFTA, when involving...
The 10th Banff Conference on Allograft Pathology was held in Banff, Canada from August 9 to 14, 2009. A total of 263 transplant clinicians, pathologists, surgeons, immunologists and researchers discussed several aspects solid organ transplants with a special focus antibody mediated graft injury. willingness the process adapt continuously response new research improve potential weaknesses, led implementation six working groups following areas: isolated v‐lesion, fibrosis scoring, glomerular...
The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of American Society Histocompatibility and Immunogenetics Pittsburgh, PA (USA) focused on refining recent updates to classification, advances from working groups, standardization molecular diagnostics. This report kidney transplant details clarifications refinements criteria chronic active (CA) T cell–mediated rejection (TCMR), borderline, antibody-mediated (ABMR). main focus sessions how address...
The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation Vancouver, Canada, reviewed clinical impact updates C4d-negative antibody-mediated rejection (ABMR) from 2013 reports active Working Groups, relationships donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, questions molecular diagnostics. use transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement diagnosis classification requires...
Short-term patient and graft outcomes continue to improve after kidney liver transplantation, with 1-year survival rates over 80%; however, improving longer-term remains a challenge. Improving the function of grafts health recipients would not only enhance quality length life, but also reduce need for retransplantation, thus increase number organs available transplant. The clinical transplant community needs identify manage those modifiable factors, decrease risk failure, outcomes.COMMIT was...
The prevalent renal transplant population presents an opportunity to observe the adaptive changes in alloimmune response over time, but such studies have been limited by uncertainties conventional biopsy diagnosis of T cell-mediated rejection (TCMR) and antibody-mediated (ABMR). To circumvent these limitations, we used microarrays methods investigate 703 unselected biopsies taken 3 days 35 years post-transplant from North American European centers. Using methods, diagnosed 205 specimens...
Abstract In kidney transplantation, day-zero biopsies are used to assess organ quality and discriminate between donor-inherited lesions those acquired post-transplantation. However, many centers do not perform such since they invasive, costly may delay the transplant procedure. We aim generate a non-invasive virtual biopsy system using routinely collected donor parameters. Using 14,032 from 17 international centers, we develop system. 11 basic parameters predict four Banff lesions:...
Background. Clinical trials in renal transplantation must use surrogate markers of long-term graft survival if conclusions are to be drawn at acceptable speed and cost. Morphologic changes transplant biopsies provide the earliest available evidence damage, "protocol" from stable grafts can used reduce number patients needed clinical trials. This approach has been inhibited by concerns over safety, but risk biopsy a kidney, with no active inflammation or acute functional impairment, never...
Histologic grading systems are used to guide diagnosis, therapy, and audit on an international basis. The reproducibility of is usually tested within small groups pathologists who have previously worked or trained together. This may underestimate the variation scoring systems. We therefore evaluated established system, Banff classification renal allograft pathology, throughout Europe. also sought improve by providing individual feedback after each 14 cases. Kappa values for all features...
Journal Article Expression of VCAM-1 in the Normal and Diseased Kidney Get access D. Seron, Seron Renal Unit Department Rheumatology, United Medical Dental Schools Guy's St. Thomas's Hospitals, CampusLondon Search for other works by this author on: Oxford Academic PubMed Google Scholar J. S. Cameron, Cameron Correspondence offprint requests to: Professor Clinical Science Laboratories, 17th Floor, Tower, Hospital, London SE1 9RT, UK. O. Haskard Nephrology Dialysis Transplantation, Volume 6,...
Abstract Exploring new immunosuppressive strategies inducing donor-specific hyporesponsiveness is an important challenge in transplantation. For this purpose, a careful immune monitoring and graft histology assessment mandatory. Here, we report the results of pilot study conducted twenty renal transplant recipients, analyzing immunomodulatory effects protocol based on induction therapy with rabbit anti-thymocyte globulin low doses, sirolimus, mofetil mycophenolate. Evolution cellular humoral...
There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients transplant glomerulopathy anti-HLA donor-specific antibodies (DSA) were eligible. estimated glomerular filtration rate (eGFR) <20 mL/min per 1.73m2 and/or severe interstitial...
The authors conducted a prospective trial to assess the feasibility of real time central molecular assessment kidney transplant biopsy samples from 10 North American or European centers. Biopsy taken 1 day 34 years posttransplantation were stabilized in RNAlater, sent via courier overnight at ambient temperature laboratory, and processed (29 h workflow) using microarrays T cell- antibody-mediated rejection (TCMR ABMR, respectively). Of 538 submitted, 519 (96%) sufficient for microarray...
Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients remain uncertain.ASCERTAIN was a 24-month, open-label, multicenter study. Kidney more than 6 months posttransplant receiving CNI (baseline glomerular filtration rate [GFR] 30-70 mL/min/1.73 m) were randomized everolimus with elimination (n=127) or minimization (n=144), continued unchanged (controls, n=123) assess the effect on...